A prospective, observational, multicenter clinical investigation evaluating the clinical outcomes of tibial and/or ankle fractures stabilizedby the temporary external fixator Galaxy UNYCO System

Organizational Data

DRKS-ID:
DRKS00011523
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2017-01-03
Last update in DRKS:
2022-08-04
Registration type:
Prospective

Acronym/abbreviation of the study

OCI 1501

URL of the study

No Entry

Brief summary in lay language

This is an international, multicentric and observational clinical study. The observed medical device, which is the Galaxy UNYCO System, is CE marked and is already used by the participating hospitals in everyday clinical practice. It is an external fixator for temporary stabilization of tibial and ankle fractures. The clinical study is planned, organized and financed by Orthofix Srl (Bussolengo, Verona - Italy), which is the sponsor. The aim of this clinical study is to collect clinical data on the medical device Galaxy UNYCO System from a representative group of patients and treating physicians. The study is expected to be conducted at 5-8 hospitals in Europe and a total of about 60 people with a tibial and / or ankle fracture will participate. The recruitment phase is planned for a period of twelve months. Each treated patient will participate in the study for approximately six months until the last follow-up visit. Therefore, the active study phase is about 18 months.

Brief summary in scientific language

This clinical investigation is a post-market, prospective, observational, multicenter and international study. The investigational device, namely the Galaxy UNYCO System, is CE marked and already used as part of the normal clinical practice of the participating investigational sites. Galaxy UNYCO System is a class IIb and CE marked medical device releasedon the European market by Orthofix Srl in August 2014. The Galaxy UNYCO System is an external fixator for the temporary stabilization of tibial and/or ankle fractures. It is a modular system including multiscrew clamps, rods and monocortical screws, whichare the most innovative components: they have been designed to avoid entry into the medullary canal and they carry the potential of avoiding contamination of this area prior to subsequent definitive treatment. The proposed observational clinical investigation fully complied with and follows all proper pre-market conformity assessment processes required to obtain a CE mark. This study has been planned as part of the Orthofix Srl post-market active surveillance strategy for the collection of data on both the clinical performance and the safety of the Galaxy UNYCO System in a representative population of patients and users. The rationale of the proposed study is to supplement, update and enhance the pre-market clinical evaluation of the Galaxy UNYCO System with real-time prospectively collected data arising from the full breadth of clinical data generated in the end-user setting. The objectives of the proposedstudy are to assess: - the clinical performance (intended as the ability to maintain fracture reduction from the time of application until removal without clinically significant changes in bone alignment and position) and - the safety of the Galaxy UNYCO System during the temporary stabilization of tibial and/or ankle fractures.

Health condition or problem studied

Free text:
Tibial and ankle fracture/s that do not allow immediate definitive treatment and having a regular indication for surgical intervention with a temporary external fixator
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Male or female adult patients who have been diagnosed with a tibial and/or ankle fracture/s that do not allow immediate definitive treatment and having a regular indication for surgical intervention with the temporary external fixator Galaxy UNYCO System are planned to be enrolled.

Endpoints

Primary outcome:
The clinical performance of the Galaxy UNYCO System will be assessed by the following primary efficacy endpoints: - proportion of patients who, in the sole and therefore qualitative judgment of the Investigator, considered at a time just before device removal have either maintained reduction or have lost a clinically significant degree of reduction from the device application; - proportion of patients who, on the basis of a quantitative software analysis performed on radiographic measurements, considered at a time just before device removal have either maintained reduction or have lost a clinically significant degree of reduction from the device application.
Secondary outcome:
And the following secondary efficacy endpoints: - extraction torque of the monocortical screws measured at device removal; - intraoperative application time; - number of intraoperative fluoroscopy shots.

Study Design

Purpose:
Treatment
Retrospective/prospective:
No Entry
Study type:
Non-interventional
Longitudinal/cross-sectional:
No Entry
Study type non-interventional:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • France
  • Germany
  • Italy
Number of study centers:
Multicenter study
Recruitment location(s):
  • University medical center Hospital: Groupe Hospitalier Universitaire Pitié Salpêtrière Department: Chirurgie Orthopédique et Traumatologique Paris
  • University medical center Institution: Technische Universität München Hospital: Klinikum rechts der Isar Department: Klinik und Poliklinik for Unfallchirurgie München
  • Medical center Hospital: Hôpital d'instruction des armées Percy Department: Chirurgie orthopédique Clamart
  • University medical center Institution: Universitätsklinikum Freiburg Department: Klinik für Orthopädie und Unfallchirurgie Freiburg
  • University medical center Institution: A.O.U. I. di Verona Hospital: Polo Chirurgico “P. Confortini” Ospedale Civile Maggiore Borgo Trento Department: U.O.C. Ortopedia e Traumatologia B Verona
  • University medical center Institution: A.O.U. Consorziale Policlinico Hospital: Policlinico "Giovanni XXIII" Department: U.O. di Ortopedia e Traumatologia I e II Universitaria Bari

Recruitment period and number of participants

Planned study start date:
2017-01-15
Actual study start date:
2017-02-28
Planned study completion date:
No Entry
Actual Study Completion Date:
2019-03-23
Target Sample Size:
60
Final Sample Size:
28

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Patient will be eligible for inclusion in the investigation if he/she: - is at least 18 years old at time of ICF signature; - is compliant in signing ICF; - has a tibial and/or ankle fracture/s requiring surgical management with an external fixator for the temporary stabilization of bone fragments prior to definitive treatment in trauma or orthopedic condition/procedures, such as: - comminuted open or closed tibial fractures - damage control orthopedics for fractures with severe soft tissue injuries - peri-prosthetic or peri-implant fractures - joint dislocations, intra- and extra-articular injuries where spanning fixation is needed - intermediate stabilization in staged surgery - infected non‑union pending second stage treatment bone-loss or other reconstructive procedures - has a regular indication for surgical intervention with Galaxy UNYCO System components according to the manufacturer’s instruction for use and in accordance with the individual Investigator judgment and normal practice parameters and decision making

Exclusion Criteria

Patient will be excluded from participation in the investigation if he/she: -has a medical condition that is a contraindication according to the manufacturer’s instruction for use, that include: - patients with mental or physiological conditions who are unwilling or incapable of following postoperative care instructions - patients with severe osteoporosis - patients with malignancy either a primary or as metastic lesion or lesions in the fracture area - patients with foreign body sensitivity; -has any conditions that in the Investigator’s opinion may interfere with the study execution or due to which the patient should not participate for safety reasons; - requires the application of, or has already in-situ the application of concomitant devices that cannot be safely removed and are therefore considered impermissible in accordance with the manufactiurer’s guidelines; - is participating in other clinical trials or has taken part in any clinical study in the last 3 months; - is likely to be lost to follow up.

Addresses

Primary Sponsor

Address:
Orthofix Srl
Via delle Nazioni, 9
37012 Bussolengo
Italy
Telephone:
+39 045 6719061
Fax:
+ 39 045 6719380
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
No

Contact for Scientific Queries

Address:
Technische Universität MünchenHospital: Klinikum rechts der IsarDepartment: Klinik und Poliklinik for Unfallchirurgie
Univ.-Prof. Dr. med. Peter Biberthaler
Ismaninger Straße 22
81675 München
Germany
Telephone:
+49 089 41402126
Fax:
+49 089 41404890
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Address:
Technische Universität MünchenHospital: Klinikum rechts der IsarDepartment: Klinik und Poliklinik for Unfallchirurgie
PD Dr Med Chlodwig Kirchhoff
Ismaninger Straße 22
81675 München
Germany
Telephone:
+49 089 41402126
Fax:
+49 089 41404890
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Technische Universität MünchenHospital: Klinikum rechts der IsarDepartment: Klinik und Poliklinik for Unfallchirurgie
Univ.-Prof. Dr. med. Peter Biberthaler
Ismaninger Straße 22
81675 München
Germany
Telephone:
+49 089 41402126
Fax:
+49 089 41404890
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Commercial (pharmaceutical industry, medical engineering industry, etc.)

Address:
Orthofix Srl
Via delle Nazioni, 9
37012 Bussolengo
Italy
Telephone:
+39 045 6719061
Fax:
+ 39 045 6719380
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission der Fakultät für Medizin der Technischen Universität München
Ismaninger Str. 22
81675 München
Germany
Telephone:
+49-89-41404371
Fax:
+49-89-41404199
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2016-06-09
Ethics committee number:
282/16 S
Vote of the Ethics Committee:
Approved
Date of the vote:
2016-10-18

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry